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After a warning of  the Society of  Gynecologic Oncology (SGO) 
in December 2013, concerning the possible increase of  dissemi-
nating tumor cells during intercorporal morcellation, the LAN-
CET ONCOLOGY published an editorial in February 2014 stat-
ing that the patient safety must be a priority in all aspects of  care 
[1].
In April 2014 the food and drug administration (FDA) discour-
aged the use of  laparoscopic morcellation in minimal-invasive 
hysterectomy or myoma surgery (MIS) [2].
The American Association of  Gynecological Laparoscopists [3] 
and the European Society of  Gynecological Endoscopy [4] stated 
the importance of  further evaluation and the necessity of  scien-
tific data-based studies before final conclusions could be taken.
As the results of  prospective, register-based studies can take sev-
eral years to be generated, we performed a retrospective single-
center evaluation of  10,731 uterine morcellations, being the biggest 
series ever, which data will be published soon. Out of  the 10,731 in-
tra-abdominal uterine morcellations in laparoscopic hysterectomy, 
81.3 % showed myomata; in those 8,720 six patients histologically 
showed to have a leiomyosarcoma (≥ 10 mitoses per high power 
field). After secondary oncological surgery and a follow-up of  ≥ 
2 years, five women were cured; one patient died due to diffuse 
intra-abdominal sarcoma spread.
Sarcomata are well known to be highly aggressive independently 
of  the surgery performed and the concomitant adjuvant radio- 
or chemotherapy. MIS in myoma-induced disease is saving many 
surgical deaths every year that would occur if  all operative entries 
would be switched to laparotomy [5].
Patients should be informed of  the uterine tissue morcellation 
risk before MIS and given the opportunity to independently de-
cide if  they prefer the alternative laparotomic route. Because of  
the high benefits of  MIS in reducing surgically-induced morbidity 
and mortality, as well as the very low risk of  intra-abdominal sar-
coma spreading during morcellation (see above), further register-
based prospective studies should be taken into account before 
changing a world-wide adopted surgical practice, applied millions 
of  times every year.
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